Efficacy and safety of long-term use of prolonged bronchodilators in patients with cardiopulmonary pathology and chronic heart failure

The correction of the broncho-obstructive syndrome in patients with CHF of ischemic genesis in combination with chronic obstructive pulmonary disease (COPD) is an important problem in real clinical practice. Aim. The purpose of this study was to determine the safety and efficacy of long-term administration of tiotropium bromide and indacaterol as part of basic therapy of patients with CHF II-III FC and COPD of moderate and severe course. Materials and methods. The study included 2 stages: at the first stage of observation, 110 patients received basic therapy for CHF and COPD for 6 months; at the 2 nd stage (duration 6-18 months), 81 patients took part in the study, divided into 3 groups for receiving bronchodilator: 1st (29 people) received tiotropium bromide as part of complex therapy, 2nd (27 people) received indacaterol, and the 3rd (25 people) - a combination of tiotropium and indacaterol). At baseline and after 6-18 months, the clinical condition, the severity of CHF and COPD were assessed according to the quality of life questionnaires, exercise tolerance in the test with 6-minute walking, and the dynamics of echocardiography, BADM, and respiratory function. The comparison group consisted of 29 patients who retired after 6 months observations from the study. Results. Long-term use of tiotropium and indacaterol and their combination in the treatment of patients with CHF II-III FC in combination with COPD is effective and safe, improves the quality of life, reduces the number and duration of ischemia episodes, positive changes in intracardiac hemodynamics, stabilizes spirometry parameters and improves the prognosis

chronic heart failure, coronary heart disease, chronic obstructive pulmonary disease, tiotropium, indacaterol, nebivolol